Biotechnology in europe

Area of Science:

• Biotechnology commercialization strategies
• Comparative analysis of biotechnology sectors

Background:

• European Economic Community (EEC) nations have intensified efforts in biotechnology commercialization.
• EEC biotechnology initiatives rival U.S. in company numbers and government investment.
• Significant overlap exists between European and U.S. biotechnology operations and investments.

Purpose of the Study:

• To examine and compare biotechnology commercialization strategies and efforts within EEC countries and the United States.
• To highlight key differences in government emphasis between European and U.S. biotechnology development.

Main Methods:

• Comparative analysis of government spending and company involvement in biotechnology.
• Examination of industry-university collaboration and industrial project support.
• Assessment of the extent of U.S. operations by European companies and vice versa.

Main Results:

• European biotechnology efforts are comparable to U.S. efforts in scale (companies and funding).
• European governments place greater emphasis on supporting industry-university collaborations and industrial projects.
• The U.S. focuses more on the support of basic research in biotechnology.

Conclusions:

• European biotechnology commercialization is a significant and growing sector, comparable to the U.S.
• Divergent government support strategies may influence the trajectory of biotechnology development in Europe versus the U.S.
• The interconnectedness of European and U.S. biotechnology markets necessitates a holistic view of global biotechnology trends.